Heart drug mavacamten under the microscope: Real-World study launches

NCT ID NCT07557498

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is following about 362 adults with a type of heart disease called obstructive hypertrophic cardiomyopathy who are taking the drug mavacamten. Researchers want to see how the drug works in real doctor's offices, not just in strict research settings. They will track things like blood pressure, heart function, and how patients and their doctors feel about the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (OHCM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Adelphi Real World

    RECRUITING

    Bollington, Macclesfield, SK10 5JB, United Kingdom

    Contact Phone: •••-•••-••••